Capital Royalty L.P. is a market pioneer and innovator in healthcare investing that focuses on intellectual property investments in FDA-approved biopharmaceutical assets through royalty bonds and other royalty monetization structures. We target investments between $25 and $200 million and work directly with leading healthcare companies, research institutions, and inventors to provide customized royalty monetization structures to meet their unique needs.

Our royalty monetizations are an attractive alternative to costly equity financings and restrictive debt financings. We help healthcare organizations fund pipeline development, make acquisitions, and expand into new markets—all with an adaptable source of capital.

In addition to the outright purchase of royalty entitlements, Capital Royalty strives to help royalty owners borrow against their royalty streams rather than forego all future revenue streams. This differentiated approach involves structuring royalty monetizations as royalty bonds or bond-like structures. Royalty bonds were first developed by Capital Royalty team members and we continue to develop creative financing structures that better match the needs of royalty owners with royalty investors. As the only investment team with experience in structuring both royalty bonds and traditional royalty monetizations, Capital Royalty is uniquely qualified to meet a broad range of financing needs for healthcare royalty owners.

We provide superior risk-adjusted returns to our investors by offering the most attractive financing alternatives to our business partners. Our investors include pension funds, insurance companies, family offices, university endowments, foundations, financial institutions, and other institutional investors. Our committed capital base provides us with the flexibility to move quickly to meet the capital needs of our business partners.